Jefferies Maintains a 'Buy' on Pfizer (PFE); First Half Sweet Spot Ahead of H2'12 Pipeline Casino
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $29.10 -1.02%
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade PFE Now!
Jefferies maintains a 'Buy' on Pfizer (NYSE: PFE) price target raised from $25 to $26.
Jefferies analyst said, "We see strong potential for outperformance in H1'12 driven by the likely approval of a best-in-class label for Eliquis and increasing visibility on the Animal Health and Nutrition disposals. We have become incrementally concerned over tofacitinib's safety profile recently and see asymmetric downside risk for an on-time approval. Meanwhile, bapineuzumab provides substantial positive asymmetry versus our current assumptions."
"Management lowered 2012 Non-GAAP EPS guidance to $2.20-$2.30 (prior $2.25-$2.35) due to FX headwinds. Our updated 2012E estimates for revenue and Non-GAAP EPS are $63.46bn (Cons. $62.98bn) and $2.27 (Cons. $2.30; guidance $2.20 - $2.30), respectively."
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.11 yesterday, with a 52 week range of $16.63-$22.17.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Jefferies analyst said, "We see strong potential for outperformance in H1'12 driven by the likely approval of a best-in-class label for Eliquis and increasing visibility on the Animal Health and Nutrition disposals. We have become incrementally concerned over tofacitinib's safety profile recently and see asymmetric downside risk for an on-time approval. Meanwhile, bapineuzumab provides substantial positive asymmetry versus our current assumptions."
"Management lowered 2012 Non-GAAP EPS guidance to $2.20-$2.30 (prior $2.25-$2.35) due to FX headwinds. Our updated 2012E estimates for revenue and Non-GAAP EPS are $63.46bn (Cons. $62.98bn) and $2.27 (Cons. $2.30; guidance $2.20 - $2.30), respectively."
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.11 yesterday, with a 52 week range of $16.63-$22.17.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Final Conversion Ratio Offered by Pfizer (PFE) for Zoetis (ZTS) Shares is 0.9898
- Lazard Raises PT on Chicago Bridge & Iron (CBI) to $75
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Samples
ginamcneil on Feb 4, 2012 05:12 AMMark as Spam | Reply to this comment
Giving away freebies and free samples is the best way for companies to introduce their products to you. Best place is "Get Official Samples" Best of all, there is no obligation on your part.